Publication | Open Access

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Hematological MalignancyLymphoid NeoplasiaCell TherapyMedicineImmunologyHematologyAutoimmunityDose-escalation TrialAdult T-cell Leukemia-lymphomaImmunotherapyOncologyCell TransplantationPhase 1